|
1
|
Matulonis UA, Sood AK, Fallowfield L,
Howitt BE, Sehouli J and Karlan BY: Ovarian cancer. Nat Rev Dis
Primers. 2:160612016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Koshiyama M, Matsumura N and Konishi I:
Subtypes of ovarian cancer and ovarian cancer screening.
Diagnostics. 7:E122017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gaya AM and Rustin GJ: Vascular disrupting
agents: A new class of drug in cancer therapy. Clin Oncol.
17:277–290. 2005. View Article : Google Scholar
|
|
4
|
Al-Abd AM, Alamoudi AJ, Abdel-Naim AB,
Neamatallah TA and Ashour OM: Anti-angiogenic agents for the
treatment of solid tumors: Potential pathways, therapy and current
strategies-A review. J Adv Res. 8:591–605. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bielenberg DR and Zetter BR: The
contribution of angiogenesis to the process of metastasis. Cancer
J. 21:267–273. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Burger RA: Overview of anti-angiogenic
agents in development for ovarian cancer. Gynecol Oncol.
121:230–238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Monk BJ, Minion LE and Coleman RL:
Anti-angiogenic agents in ovarian cancer: Past, present, and
future. Ann Oncol. 27 (Suppl):i33–i39. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chase DM, Chaplin DJ and Monk BJ: The
development and use of vascular targeted therapy in ovarian cancer.
Gynecol Oncol. 145:393–406. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fan L, Li W, Ying S, Shi L, Wang Z, Chen
G, Ye H, Wu X, Wu J, Liang G and Li X: A peptide derivative serves
as a fibroblast growth factor 2 antagonist in human gastric cancer.
Tumour Biol. 36:7233–7241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luo W, Yu Y, Wang R, He D, Wang C, Zeng X,
Chen X, Tan X, Huang T and Wu X: P7 peptides targeting bFGF
sensitize colorectal cancer cells to CPT-11. Int J Mol Med.
33:194–200. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu Y, Gao S, Li Q, Wang C, Lai X, Chen X,
Wang R, Di J, Li T, Wang W and Wu X: The FGF2-binding peptide P7
inhibits melanoma growth in vitro and in vivo. J Cancer Res Clin
Oncol. 138:1321–1328. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Q, Gao S, Yu Y, Wang W, Chen X, Wang R,
Li T, Wang C, Li X and Wu X: A novel bFGF antagonist peptide
inhibits breast cancer cell growth. Mol Med Rep. 6:210–214.
2012.PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Buys SS, Partridge E, Black A, Johnson CC,
Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B,
et al: Effect of screening on ovarian cancer mortality: The
prostate, lung, colorectal and ovarian (PLCO) cancer screening
randomized controlled trial. Jama. 305:2295–2303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Collins T, Gray K, Bista M, Skinner M,
Hardy C, Wang H, Mettetal JT and Harmer AR: Quantifying the
relationship between inhibition of VEGF receptor 2, drug-induced
blood pressure elevation and hypertension. Br J Pharmacol.
175:618–630. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hayman SR, Leung N, Grande JP and Garovic
VD: VEGF inhibition, hypertension, and renal toxicity. Curr Oncol
Rep. 14:285–294. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Arkenau HT, Brunetto AT, Barriuso J, Olmos
D, Eaton D, de Bono J, Judson I and Kaye S: Clinical benefit of new
targeted agents in phase I trials in patients with advanced
colorectal cancer. Oncology. 76:151–156. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cohn DE, Valmadre S, Resnick KE, Eaton LA,
Copeland LJ and Fowler JM: Bevacizumab and weekly taxane
chemotherapy demonstrates activity in refractory ovarian cancer.
Gynecol Oncol. 102:134–139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Crickard K, Gross JL, Crickard U, Yoonessi
M, Lele S, Herblin WF and Eidsvoog K: Basic fibroblast growth
factor and receptor expression in human ovarian cancer. Gynecol
Oncol. 55:277–284. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hill DS, Martin S, Armstrong JL, Flockhart
R, Tonison JJ, Simpson DG, Birch-Machin MA, Redfern CP and Lovat
PE: Combining the endoplasmic reticulum stress-inducing agents
bortezomib and fenretinide as a novel therapeutic strategy for
metastatic melanoma. Clin Cancer Res. 15:1192–1198. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu X, Yan Q, Huang Y, Huang H, Su Z, Xiao
J, Zeng Y, Wang Y, Nie C, Yang Y and Li X: Isolation of a novel
basic FGF-binding peptide with potent antiangiogenetic activity. J
Cell Mol Med. 14:351–356. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Binder BR, Mihaly J and Prager GW:
uPAR-uPA-PAI-1 interactions and signaling: A vascular biologist's
view. Thromb Haemost. 97:336–342. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Torng PL, Mao TL, Chan WY, Huang SC and
Lin CT: Prognostic significance of stromal metalloproteinase-2 in
ovarian adenocarcinoma and its relation to carcinoma progression.
Gynecol Oncol. 92:559–567. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schmalfeldt B, Prechtel D, Harting K,
Spathe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W
and Lengyel E: Increased expression of matrix metalloproteinases
(MMP)-2, MMP-9, and the urokinase-type plasminogen activator is
associated with progression from benign to advanced ovarian cancer.
Clin Cancer Res. 7:2396–2404. 2001.PubMed/NCBI
|
